Loading clinical trials...
Loading clinical trials...
A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
CC-930
Placebo
+2 more
Locations
22
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
UC Davis Medical Center, Division of Pulmonary and Critical Care Medicine
Sacramento, California, United States
Stanford University, Pulmonary & Critical Care Clinic
Stanford, California, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
University of Louisville
Louisville, Kentucky, United States
University of Minnesota
Minneapolis, Minnesota, United States
Start Date
January 1, 2011
Primary Completion Date
January 31, 2012
Completion Date
August 24, 2012
Last Updated
November 19, 2019
NCT02417740
NCT04429100
NCT06632444
NCT06238622
NCT06859424
NCT07299695
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions